Biovica, active in cancer monitoring, today announces that the company has received a PLA code from the AMA (American Medical Association), an important milestone in the commercialization of DiviTum® TKa in the United States.
The PLA code is a specific code for the DiviTum® TKa test issued by the AMA and enables payers and providers to readily identify our service and reduce administrative burden for providers and payers. Effective October 1, 2023, the code will be used for billing, reporting, and processing healthcare claims.
“We are happy that we have received the PLA code from the AMA. This means that our process of pricing determination for Medicare is referenced by government and commercial payers in the US during the contracting and claims processes,” says Warren Cresswell, President Biovica Americas. “This is important for patients, as some 50 percent of women with this type of breast cancer are Medicare Beneficiaries.”